Search Results - "Eberst, K"

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension by Zineh, Issam, Beitelshees, Amber L., Gaedigk, Andrea, Walker, Joseph R., Pauly, Daniel F., Eberst, Kathleen, Leeder, J. Steven, Phillips, Michael S., Gelfand, Craig A., Johnson, Julie A.

“…Objective β‐Blocker use can be associated with adverse effects that may have an impact on adherence or harm patients. The commonly prescribed β‐blocker…”
Get full text

Neuroprotective effects of a novel non-receptor-binding estrogen analogue: In vitro and in vivo analysis by RAN LIU, YANG, Shao-Hua, DAY, Arthur L, SIMPKINS, James W, PEREZ, Evelyn, KUN DON YI, WU, Samuel S, EBERST, Kathleen, PROKAI, Laszlo, PROKAI-TATRAI, Katalin, ZU YUN CAI, COVEY, Douglas F

“…Although estrogens are neuroprotective, hormonal effects limit their clinical application. Estrogen analogues with neuroprotective function but lacking…”
Get full text

Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension by ZINEH, I, BEITELSHEES, A, GAEDIGK, A, WALKER, J, PAULY, D, EBERST, K, LEEDER, J, PHILLIPS, M, GELFAND, C, JOHNSON, J

Get full text

Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects by Beitelshees, A. L., Zineh, I., Gaedigk, A., Leeder, J. S., Walker, J. R., Eberst, K., Timmerbeil, B. S., Lobmeyer, M., Pauly, D. F., Johnson, J. A.

“…We hypothesized that metoprolol adverse effects (AEs) would be dependent on S‐metoprolol concentration (Cp) and CYP2D6 phenotype. Hypertensive subjects took…”
Get full text

Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue by Saah, M, Wu, W M, Eberst, K, Marvanyos, E, Bodor, N

“…We espouse the application of a novel chemical delivery system (CDS) approach to a delivery mechanism for drug targeting to lung tissue using the…”
Get more information

Prediction of stability in pharmaceutical preparations. XXI: The analysis and kinetics of hydrolysis of a cocaine degradation product, ecgonine methyl ester, plus the pharmacokinetics of cocaine in the dog by Garrett, E R, Eberst, K, Maruhn, D

Get more information

Pharmacokinetics and bioavailabilities of hymecromone in human volunteers by Garrett, E R, Venitz, J, Eberst, K, Cerda, J J

“…Specific and ultrasensitive reverse-phase HPLC assays of the choleretic and biliary antispasmodic hymecromone (down to 0.05 ng ml-1) and its glucuronide, using…”
Get more information

Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese by Garrett, E R, Süverkrup, R S, Eberst, K, Yost, R L, O'Leary, J P

“…Intestinal bypass surgery in 4 morbidly obese female (110-150 kg) had no permanent effect on the rate or amount of sulfisoxazole absorption. The loss of weight…”
Get more information